Oftaquix (Levofloxacin Hemihydrate)

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these targets, the drug prevents bacterial cell division and leads to rapid bacterial death, providing broad‑spectrum coverage against common ocular pathogens.

The dosing regimen for Oftaquix is determined by the prescribing clinician based on the specific infection, severity and patient factors. The product is supplied as an ophthalmic solution to be instilled in the affected eye(s) as directed by a qualified healthcare professional.

Safety data for levofloxacin ophthalmic use in pregnancy and lactation are limited. The product should be used only if clearly needed and after a risk‑benefit assessment by the prescriber. Women who are pregnant, planning pregnancy or breastfeeding should discuss alternatives with their doctor.

To request Oftaquix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Oftaquix (levofloxacin) offers a broad‑spectrum fluoroquinolone option with strong activity against both Gram‑negative and Gram‑positive ocular bacteria. Compared with older agents such as ciprofloxacin, levofloxacin often provides higher potency, better tissue penetration and a lower risk of resistance development, making it a preferred choice for many clinicians.

Oftaquix should be stored at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct light, and ensure the cap is tightly closed when not in use to maintain sterility and potency.

The product is supplied as a sterile ophthalmic solution. The prescribed number of drops is instilled into the affected eye(s) using the provided dropper, typically at intervals recommended by the prescriber. Patients should avoid touching the tip of the bottle to the eye or any surface to preserve sterility.

Serious risks, although rare, include corneal epithelial toxicity or ulceration, severe allergic reactions such as Stevens‑Johnson syndrome, and systemic tendon rupture, especially in patients receiving systemic corticosteroids. Any signs of severe eye pain, vision loss, rash or swelling should prompt immediate medical attention.

Oftaquix is contraindicated in individuals with known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. Caution is advised for patients with active corneal epithelial defects, those on systemic corticosteroids, and pregnant or breastfeeding women unless the benefit outweighs the risk.